Fosun Pharma unit starts China Phase II trial of COPD drug candidate FXS7553
Fosun Pharma Subsidiary Wins Approval for Pediatric Constipation Drug in China
Fosun International Issues 1H2026 Positive Profit Alert as Core Industries Show Strong Resilience
Fosun expects 1H profit attributable to owners at RMB 1.5 billion-RMB 1.8 billion
Hong Kong Market Shifts: The Tug-of-War Between Nvidia Leverage and High-Yield ETFs
Hong Kong's Niche Sectors Signal Structural Shifts: How Institutions Are Repositioning